VEGF is the most potent angiogenic factor and VEGF signalling pathway inhibitors (VSPIs) are effective anti-cancer therapies used in the treatment of a wide range of cancers including renal, hepatocellular and thyroid cancers, gastrointestinal stromal tumours, sarcoma and others. This evidence concerns the gene VEGFA and thyroid gland carcinoma.